Discover trends, market shifts, and competitive outlooks for the typhoid vi polysaccharide vaccine industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

#What is the Projected CAGR for the Typhoid Vi Polysaccharide Vaccine Market Size from 2025 to 2034?

The market size of the typhoid Vi polysaccharide vaccine has experienced a significant surge in recent years. Its growth is projected to increase from $5.78 billion in 2024 to an impressive $6.77 billion in 2025, with a compound annual growth rate (CAGR) of 17.1%. Factors contributing to this remarkable growth during the historical period are disease prevalence, world health programs, the vaccination of travelers, government-led immunization plans, and the efficiency and safety of the vaccine.

The market for the typhoid vi polysaccharide vaccine is anticipated to witness swift expansion in the coming years, with a predicted growth to $13.36 billion in 2029 at a compound annual growth rate (CAGR) of 18.5%. The surge during this forecast period can be credited to increased immunization initiatives, a concentrated focus on global health policy, epidemiological monitoring, heightened demand in the field of travel medicine, and both environmental and societal factors. Key trends over the forecast period are likely to be investment in research and development, regulatory backing, epidemiological research, and heightened public health awareness.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=8313&type=smp

How Are Key Drivers in the Industry Acting as Catalysts for the Growth of the Typhoid Vi Polysaccharide Vaccine Market?

The increasing occurrence of typhoid is forecasted to fuel the expansion of the typhoid VI polysaccharide vaccine market. Typhoid is a potentially deadly infection caused by the bacterium Salmonella typhi, typically transmitted through contaminated food or beverages. The Typhoid Vi polysaccharide vaccine is designed to protect adults and children aged 2 and above from typhoid fever associated with Salmonella enterica serovar Typhi, S. Typhi. For example, in August 2024, based on data revealed by the UK Health Security Agency, a governmental organization based in the UK, there was a hike in laboratory-confirmed symptomatic cases of enteric fever in England, Wales, and Northern Ireland from 2021 to 2022, with S. Typhi surging from 108 to 313, S. Paratyphi A from 31 to 135, and S. Paratyphi B from 13 to 18. As such, the escalating typhoid incidence is stimulating the growth of the typhoid Vi polysaccharide vaccine market.

Which Segments in the Typhoid Vi Polysaccharide Vaccine Offer the Most Growth?

The typhoid vi polysaccharide vaccine market covered in this report is segmented –

1) By Type: Child, Adult

2) By Route Of Administration: Oral, Parenteral

3) By Application: Government Institution, Private Sector, Other Applications

Subsegments:

1) By Child: Pediatric Formulations, Age-Specific Dosages

2) By Adult: Standard Adult Formulations, High-Risk Population Formulations

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=8313&type=smp

What Are the Fastest-Growing Geographies in the Typhoid Vi Polysaccharide Vaccine Market?

Asia-Pacific was the largest region in the typhoid Vi polysaccharide vaccine market share in 2024. The regions covered in the typhoid vi polysaccharide vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Are the Current Market Growth and Trends in the Typhoid Vi Polysaccharide Vaccine Industry?

Forming strategic alliances is becoming a prominent trend in the typhoid Vi polysaccharide vaccine market. Major market players in the typhoid Vi polysaccharide vaccine field are forging partnerships to solidify their market stance. For example, in July 2022, The International Vaccine Institute, which is a South Korea-based entity centering on globally significant infectious diseases such as cholera, typhoid, shigella, and salmonella, collaborated with Moderna, an American biopharmaceutical firm. This collaboration birthed the first budget-friendly oral cholera vaccine as well as a novel typhoid conjugate vaccine.

View the full report here:

https://www.thebusinessresearchcompany.com/report/typhoid-vi-polysaccharide-vaccine-global-market-report

What Are the Key Elements That Define the Typhoid Vi Polysaccharide Vaccine Market?

Typhoid VI polysaccharide vaccine refers to the recommendation of active immunization for people aged two and up, concerning the prevention of typhoid fever caused by Salmonella typhi.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=8313

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model